Hepatocellular Adenoma (LIAD)
Overview
Hepatocellular Adenoma (HCA) is a benign liver tumor classified under Hepatobiliary Cancer in OncoTree (parent: LIVER). It is clinically important because specific molecular subtypes — particularly those harboring CTNNB1 (β-catenin) activating mutations — carry a high risk of malignant transformation to hepatocellular carcinoma (HCC). TERT promoter mutations mark the transition from HCA to HCC.
Cohorts in the corpus
- No primary HCA cohort in the corpus; data synthesized from a narrative review covering published HCC/HCA genomic, transcriptomic, and clinical-trial data through early 2014 — PMID:24735922
Recurrent alterations
- CTNNB1 (β-catenin) activating mutations — present in a high-risk HCA subtype; this molecular subtype has a high risk of malignant transformation to HCC and is an indication for surgical resection PMID:24735922
- TERT promoter mutations — detected in 17% of borderline HCA/HCC lesions and 56% of HCA with overt HCC transformation; absent in classical HCA — established as a biomarker for the HCA→HCC transition PMID:24735922
Subtypes
- CTNNB1-mutant HCA — high malignant-transformation risk; surgical resection recommended PMID:24735922
- Classical HCA (no TERT promoter mutation) — lower transformation risk PMID:24735922
Therapeutic landscape
- Surgical resection is the intervention of choice for CTNNB1-mutant HCA to prevent HCC transformation; no targeted systemic therapies catalogued for HCA in the corpus PMID:24735922
Sources
- PMID:24735922 — Pinyol et al. (2014), narrative review of HCC/HCA molecular profiling and targeted therapy landscape.
This page was processed by entity-page-writer on 2026-05-11.